Journey Medical Q2 2024 Earnings Report

Journey Medical EPS Results

• Actual EPS: -$0.17
• Consensus EPS: -$0.14
• Beat/Miss: Missed by -$0.03
• One Year Ago EPS: -$0.46

Journey Medical Revenue Results

• Actual Revenue: $14.86 million
• Expected Revenue: $13.81 million
• Beat/Miss: Beat by +$1.05 million
• YoY Revenue Growth: N/A

Journey Medical Announcement Details

• Quarter: Q2 2024
• Date: 8/12/2024
• Time: After Market Closes

Journey Medical (NASDAQ:DERM) focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.